<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: To identify novel serological biomarkers for human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), we analyzed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues using gel-assisted digestion and isobaric tags with related and absolute quantitation (iTRAQ) labeling mass spectrometry (MS) </plain></SENT>
<SENT sid="1" pm="."><plain>By comparing pairs of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues and matched <z:mpath ids='MPATH_458'>normal</z:mpath> tissues, we discovered the SEC61β with expression changes 3.3-fold and a marginal statistical significance (p=0.052) previously </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: SEC61β expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissues was further analyzed by western blotting and immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>We next assessed the putative diagnostic value of the SEC61β autoantibody as a serum marker </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Using western blotting analysis, SEC61β expression was increased 1.9-fold in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues </plain></SENT>
<SENT sid="5" pm="."><plain>Immunohistochemical analysis of 64 CRC specimens showed that SEC61β was positively detected in 64% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, but weakly or not detected in &gt;80% of the adjacent nontumor epithelial cells </plain></SENT>
<SENT sid="6" pm="."><plain>Western blot analysis with plasma samples showed that the sensitivity and specificity of the SEC61β autoantibody from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> were 79% and 75%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Importantly, the results of the SEC61β autoantibody for early detection of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> revealed a higher sensitivity of 77% than the carcinoembryonic antigen (CEA) assay </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Measurement of SEC61β autoantibody levels may provide an alternative detection indicator for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, particularly among early-stage patients </plain></SENT>
</text></document>